Vertex and CRISPR Therapeutics unveil more positive gene therapy data, but busulfan again casts a shadow over the field
Less than 12 hours after revealing a flop on its second shot for alpha-1 antitrypsin deficiency, Vertex plowed ahead with another data drop from …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
